• IMPORTANT SAFETY INFORMATION
  • U.S. FULL PRESCRIBING INFORMATION, including Boxed WARNINGS, and Medication Guide
ABILIFY
Home| Depression| Bipolar Disorder| Schizophrenia | For U.S. Healthcare Professionals
U.S. FULL PRESCRIBING INFORMATION, including Boxed WARNINGS, and Medication Guide      
IMPORTANT SAFETY INFORMATION
Antidepressants may increase suicidal thoughts or behaviors in some children, teenagers, and young adults, especially within the first few months of treatment or when the dose is changed. Depression and other serious mental illnesses are themselves associated with an increase in the risk of suicide. Patients on antidepressants and their families or caregivers should watch for new or worsening depression symptoms, unusual changes in behavior, or thoughts of suicide. Such symptoms should be reported to the patient's healthcare professional right away, especially if they are severe or occur suddenly.  
CONTINUED BELOW
  • About
    ABILIFY
    • Effectiveness of ABILIFY
    • Safety Profile of ABILIFY
    • How ABILIFY Is Thought to Work
    • What to Expect with ABILIFY
    • Personal Stories
  • About Bipolar
    Disorder
    • Understanding Bipolar Disorder
    • Symptoms of Bipolar Disorder
  • Life with Bipolar Disorder
    • Living with Bipolar Disorder
    • Talking About Bipolar Disorder
    • Information for Family and Friends
    • Healthy Living
  • Tools to Keep You on Track
    • Mood Tracker
    • Doctor Discussion Guide
    • Side Effects Checklist
    • BMI Calculator
    • Sign Up for More Information
  • Pediatric Bipolar Disorder
    • Taking ABILIFY
    • ABILIFY Safety Profile and Side Effects
    • Understanding Pediatric Bipolar Disorder
    • Approaches to Healthy Living
    • Coping and Support for Families

Manage symptoms of Bipolar Disorder.

ABILIFY is effective in treating manic or mixed symptoms of Bipolar Disorder in pediatric patients (10 to 17 years). Learn about ABILIFY
Learn more about pediatric Bipolar Disorder and its challenges. Understanding pediatric Bipolar Disorder
Nutrition, exercise, and interaction with peers can be important parts of your child's treatment plan. Learn about healthy choices

ABILIFY® (aripiprazole) is used for the acute and maintenance treatment of manic and mixed episodes of Bipolar I Disorder in pediatric patients 10 to 17 years of age.

Here you have access to useful information that may help you with your child's Bipolar I Disorder treatment plan.

Coping and Support Learn how to access support in your community, and through local chapters of national organizations.
Safety Profile and Side Effects Read commonly asked questions on Important Safety Information and side effects for ABILIFY.
Sign Up Today Register with ABILIFY to receive updates and information.
News | Site Map | Share This Page | Print This Page | Register | Unsubscribe   
Close

Share This Page

*Your Name:
*Your E-mail Address:
*Friend’s Name:
*Friend’s E-mail Address:
 
Send      Cancel

Please see U.S. FULL PRESCRIBING INFORMATION, including Boxed WARNINGS, and Medication Guide.

Close

E-mail Confirmation

Your E-mail has been sent to .

IMPORTANT SAFETY INFORMATION and INDICATION for ABILIFY® (aripiprazole)  

INDICATION: ABILIFY is indicated for:

  • Treatment of manic and mixed episodes associated with Bipolar I Disorder in adults and in pediatric patients 10 to 17 years of age

IMPORTANT SAFETY INFORMATION:

Elderly people with psychosis related to dementia (for example, an inability to perform daily activities as a result of increased memory loss), treated with antipsychotic medicines including ABILIFY, are at an increased risk of death compared to placebo. ABILIFY is not approved for the treatment of people with dementia-related psychosis (see Boxed WARNING).

Some medicines can increase suicidal thoughts and behaviors in children, teens, and young adults. Serious mental illnesses are themselves associated with an increase in the risk of suicide. When taking ABILIFY call your doctor right away if you have new or worsening mood symptoms, unusual changes in behavior, or thoughts of suicide. Patients and their caregivers should be especially observant for such symptoms within the first few months of treatment or after a change in dose.

Contraindication: Patients should not use ABILIFY if they are allergic to aripiprazole or any of the ingredients in ABILIFY. Allergic reactions have ranged from rash, hives and itching to anaphylaxis, which may include difficulty breathing, tightness in the chest, swelling of the mouth, face, lips, or tongue.

Serious side effects may include:

  • An increased risk of stroke and ministroke have been reported in clinical studies of elderly people with dementia-related psychosis
  • Very high fever, rigid muscles, shaking, confusion, sweating, or increased heart rate and blood pressure. These may be signs of a condition called neuroleptic malignant syndrome (NMS), a rare but serious side effect which could be fatal
  • Abnormal or uncontrollable movements of face, tongue, or other parts of body. These may be signs of a serious condition called tardive dyskinesia (TD), which could become permanent
  • If you have diabetes, or risk factors for diabetes (for example, obesity, family history of diabetes), or unexpected increases in thirst, urination, or hunger, your blood sugar should be monitored. Increases in blood sugar levels (hyperglycemia), in some cases serious and associated with coma or death, have been reported in patients taking ABILIFY and medicines like it

Lightheadedness or faintness caused by a sudden change in heart rate and blood pressure when rising quickly from a sitting or lying position (orthostatic hypotension) has been reported with ABILIFY.

Decreases in white blood cells (infection fighting cells) have been reported in some patients taking antipsychotic agents, including ABILIFY. Patients with a history of a significant decrease in white blood cell (WBC) count or who have experienced a low WBC count due to drug therapy should have their blood tested and monitored during the first few months of therapy.

ABILIFY and medicines like it can affect your judgment, thinking, or motor skills. You should not drive or operate hazardous machinery until you know how ABILIFY affects you.

Medicines like ABILIFY can impact your body’s ability to reduce body temperature; you should avoid overheating and dehydration.

ABILIFY and medicines like it have been associated with swallowing problems (dysphagia). If you had or have swallowing problems, you should tell your healthcare professional.

Tell your healthcare professional if you have a history of, or are at risk for seizures, or are pregnant or intend to become pregnant, and about all prescription and non-prescription medicines you are taking or plan to take, since there are some risks for drug interactions.

While taking ABILIFY, avoid:

  • Drinking alcohol
  • Breast-feeding an infant

Most common side effects (≥10%) from all clinical trials involving adults or pediatric patients include:

  • ADULTS: Nausea, vomiting, constipation, headache, dizziness, an inner sense of restlessness or need to move (akathisia), anxiety, insomnia, and restlessness
  • PEDIATRIC PATIENTS (10 to 17 years): Extrapyramidal disorder (for example, uncontrolled movement disorders or muscle disturbances such as restlessness, tremors, and muscle stiffness), headache, sleepiness, and nausea

It is important to contact your healthcare professional if you experience prolonged, abnormal muscle spasms or contractions which may be signs of a condition called dystonia.

For patients who must limit their sugar intake, ABILIFY Oral Solution contains sugar.

For patients with phenylketonuria or PKU, ABILIFY DISCMELT® (aripiprazole) contains phenylalanine.

If you have any questions about your health or medicines, talk to your healthcare professional.

Please see accompanying FULL PRESCRIBING INFORMATION, including Boxed WARNINGS, and Medication Guide, for ABILIFY.

570US09WA16601    September 2009    0309W-1978

© 2009  Otsuka America Pharmaceutical, Inc. All Rights Reserved.

Legal Notice | Privacy Policy | Use of Cookies
The individuals who appear on this page are for illustrative purposes only. Any person depicted here is a model and not an actual patient.